Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Current Deferred Revenue (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Current Deferred Revenue for 15 consecutive years, with $3.8 million as the latest value for Q4 2024.

  • On a quarterly basis, Current Deferred Revenue fell 15.57% to $3.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was $3.8 million, a 15.57% decrease, with the full-year FY2024 number at $3.8 million, down 15.57% from a year prior.
  • Current Deferred Revenue was $3.8 million for Q4 2024 at Harvard Bioscience, up from $3.7 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $4.5 million in Q4 2023 to a low of $3.4 million in Q4 2022.
  • A 5-year average of $3.8 million and a median of $3.7 million in 2021 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: dropped 21.0% in 2022, then surged 33.77% in 2023.
  • Harvard Bioscience's Current Deferred Revenue stood at $3.8 million in 2020, then increased by 13.13% to $4.3 million in 2021, then fell by 21.0% to $3.4 million in 2022, then skyrocketed by 33.77% to $4.5 million in 2023, then dropped by 15.57% to $3.8 million in 2024.
  • Per Business Quant, the three most recent readings for HBIO's Current Deferred Revenue are $3.8 million (Q4 2024), $3.7 million (Q3 2024), and $4.0 million (Q2 2024).